Guidant Johnson & Johnson vote ahead, but more ICD failures
This article was originally published in Clinica
Executive Summary
Guidant's shareholders will meet at an EGM on January 31 to vote on whether to accept the $21.5bn offer for the company from Johnson & Johnson. J&J's offer is $3.9bn less than its late-2004 bid of $25.4bn, but Guidant's product recalls in the summer forced J&J to review its offer in November. The date of the vote was set following the Securities and Exchange Commission's declaration on December 28 that the amended and restated merger agreement was "effective".
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.